{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T06:35:06Z","timestamp":1772692506147,"version":"3.50.1"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The leucine rich repeat containing 3B (LRRC3B) gene is a tumor suppressor gene involved in the anti-tumor immune microenvironment. Expression of LRRC3B and DNA methylation at the LRRC3B promoter region may serve as a useful marker to predict response to anti-PD-1 therapy. However, no studies have yet systematically explored the protective role of LRRC3B methylation in tumor progression and immunity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Expression of LRRC3B of 33 cancer types in The Cancer Genome Atlas (TCGA) was downloaded from UCSC Xena (<jats:uri>http:\/\/xena.ucsc.edu\/<\/jats:uri>). And, we evaluated the differential expression of LRRC3B according to tumor stage, overall survival, and characteristics of the tumor microenvironment. The immunotherapeutic cohorts included IMvigor21, GSE119144, and GSE72308 which were obtained from the Gene Expression Omnibus database. We conducted pearson correlation analysis of LRRC3B and tumor microenvironment (TME) in pan-cancer. Also, six immune cell types (B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells) and tumor purity were analyzed using the Tumor IMmune Estimation Resource (TIMER1.0) (Tumor IMmune Estimation Resource (TIMER2.0). And, a \u201csilencing score\u201d model base on LRRC3B promoter methylation to predict overall survival (OS) by multivariate Cox regression analysis was constructed. Finally, the model was applied to predict anti-PD-1 therapy in non-small cell lung cancer (NSCLC) and breast cancer (BRCA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>LRRC3B expression associated with less tumor invasion, less severe tumor stage, and decreased metastasis. The inactivation of LRRC3B promoted the enrichment of immuneosuppressive cells, including myeloid-derived suppressor cells (MDSCs), cancer-associated fibroblasts (CAFs), M2 subtype of tumor-associated macrophages (M2-TAMs), M1 subtype of tumor-associated macrophages (M1-TAMs), and regulatory T (Treg) cells. A high silencing score was significantly associated with immune inhibition, low expression of LRRC3B, poor patient survival, and activation of cancer-related pathways.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our comprehensive analysis demonstrated the potential role of LRRC3B in the anti-tumor microenvironment, clinicopathological features of cancer, and disease prognosis. It suggested that LRRC3B methylation could be used as a powerful biomarker to predict immunotherapy responses in NSCLC and BRCA.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.959868","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T07:53:25Z","timestamp":1674546805000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy"],"prefix":"10.3389","volume":"14","author":[{"given":"Linfeng","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sha","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-na","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuanye","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaodong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1101\/gr.1293003","article-title":"The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: A bioinformatics assessment","volume":"13","author":"Clark","year":"2003","journal-title":"Genome Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-440x(01)00266-4","article-title":"The leucine-rich repeat as a protein recognition motif","volume":"11","author":"Kobe","year":"2001","journal-title":"Curr Opin Struct Biol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/374183a0","article-title":"A structural basis of the interactions between leucine-rich repeats and protein ligands","volume":"374","author":"Kobe","year":"1995","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1110\/ps.4010102","article-title":"Assessment of the ability to model proteins with leucine-rich repeats in light of the latest structural information","volume":"11","author":"Kajava","year":"2002","journal-title":"Protein Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-0667","article-title":"LRRC3B, encoding a leucine-rich repeat-containing protein, is a putative tumor suppressor gene in gastric cancer","volume":"68","author":"Kim","year":"2008","journal-title":"Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.1998.1643","article-title":"Structural diversity of leucine-rich repeat proteins","volume":"277","author":"Kajava","year":"1998","journal-title":"J Mol Biol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1146\/annurev.immunol.24.021605.090542","article-title":"The evolution of adaptive immunity","volume":"24","author":"Pancer","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s12013-014-0018-1","article-title":"The clinical value of LRRC3B gene expression and promoter hypermethylation in breast carcinomas","volume":"70","author":"Wang","year":"2014","journal-title":"Cell Biochem Biophys"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3779\/j.issn.1009-3419.2016.04.01","article-title":"[LRRC3B is downregulated in non-small cell lung cancer and connected with cell proliferation and invasion]","volume":"19","author":"Kan","year":"2016","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra023075","article-title":"Gene silencing in cancer in association with promoter hypermethylation","volume":"349","author":"Herman","year":"2003","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1799","article-title":"Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction","volume":"6","author":"Baylin","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1045","article-title":"The power and the promise of DNA methylation markers","volume":"3","author":"Laird","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-5-44","article-title":"Tumor suppressor gene methylation in follicular lymphoma: A comprehensive review","volume":"5","author":"Hayslip","year":"2006","journal-title":"Mol Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.11.017","article-title":"Methylation of tumor suppressor gene CDH13 and SHP1 promoters and their epigenetic regulation by the UHRF1\/PRMT5 complex in endometrial carcinoma","volume":"140","author":"Sheng","year":"2016","journal-title":"Gynecol Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2217\/epi.11.65","article-title":"Global DNA methylation and tumor suppressor gene promoter methylation and gastric cancer risk in an omani Arab population","volume":"3","author":"Rusiecki","year":"2011","journal-title":"Epigenomics-Uk"},{"key":"B16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/00365520802400834","article-title":"Epigenetic silencing of LRRC3B in colorectal cancer","volume":"44","author":"Tian","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-18-0454","article-title":"DNA Methylation of LRRC3B: A biomarker for survival of early-stage non-small cell lung cancer patients","volume":"27","author":"Guo","year":"2018","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2011.681","article-title":"Methylation pattern of the putative tumor-suppressor gene LRRC3B promoter in clear cell renal cell carcinomas","volume":"5","author":"Kondratov","year":"2012","journal-title":"Mol Med Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1006\/abio.1999.4461","article-title":"Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction","volume":"278","author":"Johnson","year":"2000","journal-title":"Anal Biochem"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01399","article-title":"Lipid metabolic pathways confer the immunosuppressive function of myeloid-derived suppressor cells in tumor","volume":"10","author":"Yan","year":"2019","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.01.011","article-title":"Fibroblast heterogeneity and immunosuppressive environment in human breast cancer","volume":"33","author":"Costa","year":"2018","journal-title":"Cancer Cell"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/s1471-4906(02)02302-5","article-title":"Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes","volume":"23","author":"Mantovani","year":"2002","journal-title":"Trends Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-019-00741-8","article-title":"Treg cells in autoimmunity: From identification to treg-based therapies","volume":"41","author":"Goschl","year":"2019","journal-title":"Semin Immunopathol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107468","article-title":"pRRophetic: an r package for prediction of clinical chemotherapeutic response from tumor gene expression levels","volume":"9","author":"Geeleher","year":"2014","journal-title":"PloS One"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1038\/s41467-019-12159-9","article-title":"DNA Methylation loss promotes immune evasion of tumours with high mutation and copy number load","volume":"10","author":"Jung","year":"2019","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91095","article-title":"DNA Methylation-based immune response signature improves patient diagnosis in multiple cancers","volume":"127","author":"Jeschke","year":"2017","journal-title":"J Clin Invest"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.09.082","article-title":"Pan-cancer landscape of aberrant DNA methylation across human tumors","volume":"25","author":"Saghafinia","year":"2018","journal-title":"Cell Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-015-3833-0","article-title":"LRRC3B is downregulated in non-small-cell lung cancer and inhibits cancer cell proliferation and invasion","volume":"37","author":"Kan","year":"2016","journal-title":"Tumour Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.781660","article-title":"Regulating histone deacetylase signaling pathways of myeloid-derived suppressor cells enhanced T cell-based immunotherapy","volume":"13","author":"Adeshakin","year":"2022","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20182005","article-title":"TIPE2 specifies the functional polarization of myeloid-derived suppressor cells during tumorigenesis","volume":"217","author":"Yan","year":"2020","journal-title":"J Exp Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2021.104286","article-title":"Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy","volume":"362","author":"Adeshakin","year":"2021","journal-title":"Cell Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/ni1102-999","article-title":"Natural selection of tumor variants in the generation of \"tumor escape\" phenotypes","volume":"3","author":"Khong","year":"2002","journal-title":"Nat Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/s0959-437x(99)00041-6","article-title":"Tumor suppressor genes","volume":"10","author":"Macleod","year":"2000","journal-title":"Curr Opin Genet Dev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.10.010","article-title":"Deubiquitination and stabilization of PD-L1 by CSN5","volume":"30","author":"Lim","year":"2016","journal-title":"Cancer Cell"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2004.tb02195.x","article-title":"Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage","volume":"95","author":"Yoshida","year":"2004","journal-title":"Cancer Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4154","article-title":"Histone lysine demethylases as targets for anticancer therapy","volume":"12","author":"Hojfeldt","year":"2013","journal-title":"Nat Rev Drug Discovery"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2012.01.019","article-title":"LRRC3B gene is frequently epigenetically inactivated in several epithelial malignancies and inhibits cell growth and replication","volume":"94","author":"Haraldson","year":"2012","journal-title":"Biochimie"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30284-4","article-title":"Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: A multicentre, retrospective analysis","volume":"6","author":"Duruisseaux","year":"2018","journal-title":"Lancet Respir Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B42","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1600-065x.1971.tb00461.x","article-title":"Immunological surveillance in neoplasia","volume":"7","author":"Burnet","year":"1971","journal-title":"Transplant Rev"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.96793","article-title":"CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients","volume":"3","author":"Goltz","year":"2018","journal-title":"JCI Insight"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/nature15520","article-title":"Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy","volume":"527","author":"Peng","year":"2015","journal-title":"Nature"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.959868\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T14:45:42Z","timestamp":1675176342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.959868\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,24]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2023.959868"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.959868","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,24]]},"article-number":"959868"}}